机译:单独抗PD1治疗后同种异体干细胞移植在复发/难治性Hodgkin淋巴瘤中的优越性:来自法国早期访问计划的现实世界证据
Univ Hosp Rennes Clin Hematol Rennes France;
Univ Hosp Rennes Clin Hematol Rennes France;
CHU Lille Serv Malad Sang Lille France;
Paoli Calmette Inst Dept Hematol Marseille France;
Univ Hosp Dijon Dept Hematol Dijon France;
Ctr Henri Becquerel Dept Hematol Rouen France;
Cochin Hosp Dept Hematol Paris France;
Inst Bergonie Bordeaux France;
Princesse Grace Hosp Dept Med Oncol Monaco Monaco;
CHU Grenoble La Tronche France;
Univ Hosp Bordeaux Hematol Clin Pessac France;
Angers Hosp Hematol Dept Angers France;
Ctr Hosp Lyon Sud Hematol Dept Pierre Benite France;
Univ Hosp Brest Dept Hematol Brest France;
Hop St Antoine Paris France;
Ctr Leon Berard Lyon France;
Hop Robert Debre CHU Reims Reims France;
IUCT Oncopole Hematol Dept Toulouse France;
Inst Gustave Roussy Med Imaging Dept Villejuif France;
Hop St Louis AP HP Hematol Dept Paris France;
Univ Hosp Pontchaillou Clin Hematol Rennes France;
机译:单独抗PD1治疗后同种异体干细胞移植在复发/难治性Hodgkin淋巴瘤中的优越性:来自法国早期访问计划的现实世界证据
机译:Pembrolizumab单药治疗初级耐火经典霍奇金淋巴瘤淋巴瘤,后者复制后复制后爆发性干细胞移植和/或Brentuximab Vedotin治疗:Keynote-087亚组分析
机译:60岁或以上难治性或复发性经典霍奇金淋巴瘤患者的自体干细胞移植:法国骨髓移植和细胞治疗学会(SFGM-TC)的回顾性分析
机译:常规化疗后复发和抗PD1治疗复发时经典霍奇金淋巴瘤微环境中程序性细胞死亡蛋白1(PD1)的表达
机译:60岁或以上耐火或复发古典霍奇金淋巴瘤的患者的自体干细胞移植:来自法国骨髓移植和细胞疗法的法国社会的回顾性分析(SFGM-TC)